| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802595301023 | 259530102 | MEDAXONE PS.INJ.SOL 1000MG/VIAL (IV) BTx10 VIALS (χωρίς διαλύτη) (χωρίς διαλύτη) | 25.69 | 26.95 | 37.14 |
| 05/2018 | 2802595302013 | 259530201 | MEDAXONE PD.SOL.INF 2000MG/VIAL BTx1VIAL | 5.42 | 5.69 | 7.84 |
For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death.
5.8-8.7 hours
Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds.
* 5.78 to 13.5 L
* 0.58 - 1.45 L/h [healthy adults receiving 0.15-3 g of CEFTRIAXONE]